TD Cowen analyst Brendan Smith has maintained their bullish stance on ARWR stock, giving a Buy rating on January 30.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Brendan Smith has given his Buy rating due to a combination of factors that highlight Arrowhead Pharmaceuticals’ strong potential for growth and value creation. The recent closure of a significant licensing deal with Sarepta provides Arrowhead with an upfront payment of $825 million, a crucial influx of capital that secures the company’s financial position well into the future and allows it to focus on its core therapeutic areas.
Furthermore, the anticipated launch of plozasiran, an ApoC3-lowering RNAi drug, as a treatment for familial chylomicronemia syndrome (FCS) by late 2025, is poised to be a pivotal milestone. Despite the limited market size for FCS, the approval and subsequent launch of plozasiran will strengthen Arrowhead’s competitive stance in the substantially larger severe hypertriglyceridemia (SHTG) market, which could significantly drive revenue growth. These strategic developments and financial underpinnings underscore the Buy recommendation.
In another report released on January 30, RBC Capital also assigned a Buy rating to the stock with a $42.00 price target.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARWR in relation to earlier this year.